Solvent Choice Effects in Pharmaceutical API Synthesis is a specialized topic that plays a pivotal role in the development and manufacturing of active pharmaceutical ingredients (APIs). The molecular characterization of the solvents or solvent systems used in API synthesis is critical, as they can influence reaction selectivity, product yield, impurity profiles, and scalability. For unambiguous identification and reference, Solvent Choice Effects in Pharmaceutical API Synthesis is associated with a specific CAS number, which supports traceability in regulated supply chains. Its molecular formula and weight are core parameters recognized by the pharmaceutical sector, with the IUPAC name and InChIKey providing international consistency in scientific communication. As a reagent, the selection and application of this chemical are central to synthetic process development and control.
The physical and chemical specifications of reagents and solvents are fundamental to their safe and effective use in API synthesis. Key properties such as boiling point, melting point, density, flash point, and vapor pressure delineate the operational envelope for solvent-based processes. Only values confirmed by internationally recognized sources are referenced in standard pharmaceutical procurement and quality documentation.
Compliance with international regulatory frameworks is an essential aspect of modern pharmaceutical manufacturing. The status under REACH—including the relevant Article and tonnage band—provides assurance regarding the chemical’s registration for safe use in the European Economic Area. Inclusion on the TSCA inventory, along with the appropriate section reference, attests to its compliant status in the United States market. Where applicable, adherence to ICH Q3C(R8) supports solvent residue controls conforming to the latest internationally harmonized limits governing pharmaceutical excipients and process reagents. GHS hazard classification data is critical for workplace safety, encompassing all specified H-phrases, pictograms, and signal words for handler protection. Pharmacopeia references, denoted by specific chapter numbers, are required for integration into monograph-driven manufacturing environments. When available, OSHA PEL and NIOSH REL information further bolster worker protection programs.
The selection of solvent systems or single solvents directly informs the synthetic strategy for key pharmaceutical targets. As a reagent, Solvent Choice Effects in Pharmaceutical API Synthesis is regularly referenced in both early- and late-stage process development, impacting yield and purity in numerous small molecule and complex API routes. Process chemists rely on a thorough understanding of solvent effects to optimize conditions for drug substance synthesis, impurity management, and green chemistry initiatives. It is not intended for therapeutic application but is integral to the quality-driven manufacture of specific target drugs cited in published route maps or patent literature.
Packaging for Solvent Choice Effects in Pharmaceutical API Synthesis follows established industrial norms, with availability typically in 25-kilogram and 200-kilogram drums as well as intermediate bulk containers for larger volume needs. Recommended storage conditions should align with chemical stability data derived from GHS labeling and best practices, ensuring the reagent is maintained in its original, sealed packaging, away from direct sunlight, heat sources, and moisture. The benchmark shelf life for this chemical class is set by prevailing industry guidance, subject to conditions of storage and intended use.
Sources for the data reported in this article include the compound’s PubChem entry at https://pubchem.ncbi.nlm.nih.gov/compound/{cid}, authoritative physical property data curated by NIST at https://webbook.nist.gov/cgi/cbook.cgi?Name={cas_number}, compliance and registration details from ECHA at {echa_url}, and regulatory inventory status verified at the EPA’s TSCA inventory at https://www.epa.gov/tsca-inventory.
Related Articles
